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Abstract
Reverse transcriptase (RT) plays an essential role in HIV-1 replication, and inhibition of this enzyme is a key component of
HIV-treatment. However, the use of RT inhibitors can lead to the emergence of drug-resistant variants. Until recently, most
clinically relevant resistance mutations were found in the polymerase domain of RT. Lately, an increasing number of
resistance mutations has been identified in the connection and RNaseH domain. To further explore the role of these
domains we analyzed the complete RT sequence of HIV-1 subtype B patients failing therapy. Position A/T400 in the
connection subdomain is polymorphic, but the proportion of T400 increases from 41% in naı¨ve patients to 72% in patients
failing therapy. Previous studies suggested a role for threonine in conferring resistance to nucleoside RT inhibitors. Here we
report that T400 also mediates resistance to non-nucleoside RT inhibitors. The susceptibility to NVP and EFV was reduced 5-
fold and 2-fold, respectively, in the wild-type subtype B NL4.3 background. We show that substitution A400T reduces the
RNaseH activity. The changes in enzyme activity are remarkable given the distance to both the polymerase and RNaseH
active sites. Molecular dynamics simulations were performed, which provide a novel atomistic mechanism for the reduction
in RNaseH activity induced by T400. Substitution A400T was found to change the conformation of the RNaseH primer grip
region. Formation of an additional hydrogen bond between residue T400 and E396 may play a role in this structural change.
The slower degradation of the viral RNA genome may provide more time for dissociation of the bound NNRTI from the
stalled RT-template/primer complex, after which reverse transcription can resume.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) converts the viral RNA genome to a double-
stranded DNA, which subsequently becomes integrated into the
host genome. RT contains multiple enzymatic activities, including
both DNA-dependent and RNA-dependent DNA polymerase
activities and RNaseH activity, which are required to mediate the
complex process of reverse transcription [1]. RT is a heterodimer
composed of 66-kDa (p66) and 51-kDa (p51) subunits. The
catalytic p66 subunit is composed of two domains: the polymerase
domain, containing the fingers, palm, thumb and connection
subdomains, as well as the ribonuclease H (RNaseH) domain [2].
The p51 subunit has no enzymatic function, and has been
proposed to provide structural support to p66.
Because of the essential role of RT in HIV-1 replication,
inhibition of this enzyme is a major component of the treatment
for HIV infection. There are two classes of approved drugs that
target RT: the nucleos(t)ide RT inhibitors (NRTIs) and the non-
nucleoside RT inhibitors (NNRTIs). NRTIs are nucleoside
analogues that lack the 39-OH group required for formation of a
phosphodiester bond with the next incoming nucleotide [3,4].
Once incorporated into the nascent viral DNA, they act as chain
terminators. On the other hand, NNRTIs bind to a pocket near
the polymerase active site [5,6]. Binding results in a conforma-
tional change in RT that inhibits polymerization. Both classes of
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drugs have been successfully used as key components of highly
active antiretroviral therapies in combination with protease,
integrase, and entry inhibitors [7]. However, as is the case with
all antiviral drugs, prolonged use can lead to the emergence of
drug-resistant HIV variants. The virus can become resistant to
NRTIs through two mechanisms [8,9]. Increased discrimination
against the nucleoside analogue can prevent its incorporation. The
polymerase domain mutations M184V, K65R and Q151M
mediate resistance by the discrimination mechanism [10–12].
Alternatively, the ability to excise and remove chain terminators
from blocked DNA chains may be enhanced, allowing DNA
synthesis to resume [13]. The polymerase domain mutations
M41L, D67N, K70R, L210W, T215F/Y, and K219Q/E,
typically referred to as thymidine analogue resistance mutations
(TAMs) are selected during treatment with zidovudine (AZT) [14],
and mediate resistance by an excision mechanism. The selection of
drug resistance mutations can lead to a reduction in viral
replication [15,16]. For instance, M184V is selected during
treatment with lamivudine (3TC) and emtricitabine (FTC) [17],
which changes the well-conserved YMDD catalytic domain,
resulting in reduced polymerase activity of the RT enzyme [18–
20]. Resistance to NNRTIs occurs as a result of mutations that
decrease binding of the NNRTI, for example by mutations
K103N or Y181C [21,22].
Until recently, almost all clinically relevant NRTI and NNRTI
resistance mutations were found in the polymerase domain of RT.
Lately, an increasing number of mutations in the connection and
RNaseH domains of RT have been shown to play a role in
resistance [23–28]. To further explore the role of these domains,
we analyzed the complete RT sequence of HIV-1 subtype B
patients failing therapy. Position A/T400 is polymorphic in
untreated individuals, however T400 occurs more frequently in
patients failing therapy. Previous studies reported the association
of T400 with NRTI resistance in HIV-1 subtype B [28,29] and
subtype AE [30,31] and C [32]. Here we report that T400 also
mediates resistance to the NNRTIs nevirapine (NVP) and
efavirenz (EFV). Moreover, we explored the molecular mecha-
nisms involved in resistance and show that it reduces RNaseH
activity. Computer simulations provide a powerful tool that allows
us to elucidate the atomistic origins of such changes in protein
function [33]. Here we apply molecular dynamics simulations
techniques to model the effects of the alanine to threonine change
at position 400 on RT structure at the atomistic level. This
demonstrated that an additional hydrogen bond is formed
between T400 and E396 that changes the conformation of the
RNaseH primer grip region. As proposed previously, the slower
degradation of the viral RNA genome may provide more time for
dissociation of the NNRTI from the stalled RT-template/primer
complex [27,34,35]. Consequently, the mutant enzyme can
resume reverse transcription, which results in enhanced NNRTI
resistance.
Materials and Methods
Ethics statement
This study has been approved by the Agence Nationale de
Recherches sur le SIDA AC11 resistance ethics committee.
Written consent was given by the patients for their information
to be stored in the hospital database and used for research.
Analysis of HIV-1 subtype B sequences
The complete RT sequences of 135 HIV-1 subtype B patients
monitored at Pitie´-Salpeˆtrie`re Hospital, Paris, France, were
analyzed. Of these patients, 48 never received antiretroviral
treatment, whereas 87 were treated with RTI and showed
virologic failure with a plasma HIV-1 RNA.1000 copies/mL.
The antiretroviral treatment histories of treated patients were well-
characterized by reviewing their medical records. For sequencing
analysis, HIV-1 RNA was purified from 1 ml of plasma after
ultracentrifugation. The entire RT coding region was amplified
and sequenced from aminoacid (AA) 1 to 560 [36,37]. Genotyping
was performed by using an ABI 3100 Genetic Analyser (PE
Applied Biosystems), the sequences were analysed using the
Sequence Navigator software (PE Applied Biosystems) and
reported as AA changes with respect to the HIV-1 subtype B
consensus sequence (Stanford HIV Drug Resistance database).
The association between the presence of a mutation and the
treatment status was determined using the Fischer’s exact test.
Statistical significance of the associations was determined by
applying the False Discovery Rate method of Benjamini-Hochberg
[38]. This method was used to adjust for multiple testing.
Considering that m tests were computed and that the raw p-
values (unadjusted p-values) were ordered as p1,p2,p3,…,pm.
The adjusted p-values, noted p*, were given by:
pm~pm
pm{1~min pm,
m
m{1
h i
pm{1
 
pm{2~min pm{1,
m
m{2
h i
pm{2
 
:::
To assess significant prognostic factors of the A400T substitu-
tion a logistic regression model was used. Variables providing a p
value ,0.10 of the association test were potentially included in a
final multivariate model.
In addition, the HIV Sequence Database in Los Alamos
(http://www.hiv.lanl.gov/) and the HIV Drug Resistance Data-
base in Stanford (http://hivdb.stanford.edu) were used to analyze
the prevalence of T400 in HIV-1 subtype B sequences.
DNA constructs
The pNL4.3-XN construct (a kind gift from Johnson Mak) was
derived from the NL4.3 infectious molecular clone of HIV-1 [39]
and was engineered with silent mutations that introduce XbaI and
NotI restrictions sites at nucleotides 2319 and 3938, respectively
[23]. This clone was shown to have wild-type levels of infectivity.
The proviral clones pNL4.3-XN with mutations M184V and
M41L+T215Y (TAM) were described previously [40]. For
mutation of the RT gene, we used the construct pBS-RT, which
contains the ApaI-SalI fragment of pNL4.3-XN (positions 2006–
5785) cloned into pBluescript (Agilent Technologies). The A400T
substitution was introduced using the QuickChange Site-Directed
Mutagenesis Kit (Agilent Technologies), according to the manu-
facturer’s protocol. The substitution was verified by sequencing
analysis and cloned into pNL4.3-XN wild-type, M184V and TAM
proviral clones using the AgeI-NotI (positions 3486–3938)
restriction sites.
Cells and viruses
293T cells were grown in Dulbecco’s modified Eagle’s medium
containing 10% fetal calf serum (FCS) at 37uC and 5% CO2. For
generation of the HIV-1 virus stocks, 293T cells were transiently
transfected using the calcium phosphate method (CalPhos kit,
Clontech), according to the manufacturers’ protocol. Three days
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after transfection, the culture medium was centrifuged at
1,600 rpm for 10 min to remove cells, and subsequently filtered
through a 0.45 mm pore-size filter. The virus stocks were stored at
280uC. Virus production was determined by measuring the
capsid (CA)-p24 levels by enzyme-linked immunosorbent assay
(ELISA) (Aalto).
SupT1 T cells were grown in RPMI 1640 medium supple-
mented with 10% FCS at 37uC and 5% CO2. The replication
capacity of the viruses was studied in SupT1 cells. Therefore,
0.5*106 cells were seeded in a 25-cm2 culture flask containing 5 ml
of culture medium. The cells were infected with equal amounts of
virus, 50 ng based on CA-p24. Virus production was monitored
by measuring the amount of CA-p24 in the culture medium at
several days after infection.
The MT4-LTR-EGFP cell line [41] was maintained in RPMI
1640 supplemented with 10% FCS, 0.02% gentamicin and 0.8%
G418 at 37uC and 5% CO2.
Drug susceptibility assays
The assay was performed as described previously [41]. Briefly,
virus stocks were titrated and equal amounts of infectious virus
were used to infect MT4-LTR-EGFP cells in the presence or
absence of RTI. Four-fold dilutions were used for all RTIs, the
range of dilutions used for each drug was a function of the IC50
value of the respective compound. After 3 days, EGFP expression
was determined by fluorescent microscopy. The results were
expressed as IC50 values, defined as the concentration of
compound achieving 50% inhibition of the virus-induced EGFP
signals as compared to the untreated virus-infected control cells.
The ratio between the A400T and wild-type virus IC50 gives the
fold-change value, as an indicator of the level of resistance
mediated by the substitution. The RT inhibitors zidovudine
(AZT), didanosine (ddI), stavudine (d4T) lamivudine (3TC),
emtricitabine (FTC), abacavir (ABC), tenofovir (TDF), nevirapine
(NVP) and efavirenz (EFV) were purchased from Toronto
Research Chemicals Inc. Etravirine (ETR) is a GMP manufac-
tured Johnson & Johnson compound.
Virion-derived RT
293T cells were transiently transfected as described above.
Three days after transfection, the culture medium was centrifuged
at 1,600 rpm for 10 min to remove cells, and filtered through a
0.45 mm pore-size filter. The virions were pelleted by centrifuga-
tion at 25,000 rpm for 60 min in a Beckman SW28 rotor. Virions
were resuspended in 500 ml of NP buffer (50 mM TRIS-HCl,
pH 7.5, 50 mM NaCl, 0.5% NP40), and aliquots were stored at
220uC.
Polymerase assays
Minus-strand DNA synthesis was initiated on a 51-nt HIV-1
RNA template, representing the HIV-1 primer binding site region
(59-uggaaaaucucuagcaguggcgcccgaacagggacuugaaagcga-aaguaa-
39) using a 21-nt DNA primer, complementary to the 18-nt HIV-1
PBS sequence with 3 additional nts at its 59-end (59-
CAAGTCCCTGTTCGGGCGCCA-39). The DNA primer was
59-end-labeled with c-32P-ATP and T4 polynucleotide kinase
(NEB). For annealing, 50 ng of RNA template was incubated with
65 ng of labeled DNA primer in 15 ml annealing buffer (83 mM
TRIS-HCl, pH 7.5, 125 mM KCl) for 10 min at 65uC, followed
by snap-cooling on ice. Polymerization was initiated by the
addition of 100 ng (based on CA-p24) of virus lysate in 40 ul of
RT buffer (50 mM TRIS-HCl, pH 7.5, 50 mM KCl, 10 mM
DTT, 10 mM dNTPs, 3 mM MgCl2). The reactions were
incubated for 3, 7 and 15 min at 37uC, then stopped by the
addition of formamide loading buffer, and analyzed on 12%
denaturing sequencing gels. Products were quantified using the
Typhoon imaging system.
RNaseH assays
The 51-nt HIV-1 RNA template was 59-end-labeled with c-32P-
ATP and T4 polynucleotide kinase (NEB). For annealing, 10 ng of
labelled RNA template was incubated with 10 ng of the DNA
primer in 10 ml annealing buffer (83 mM TRIS-HCl, pH 7.5,
125 mM KCl) for 10 min at 65uC, followed by snap-cooling on
ice. The primer/template complex was incubated with 50 ng
(based on CA-p24) of virus lysate in 40 ul of RH buffer (50 mM
TRIS-HCl, pH 7.5, 50 mM KCl, 10 mM DTT, 1 mM EDTA).
The reaction was started by the addition of 6 mM MgCl2 and
incubated for 3, 7, 20 and 40 min at 37uC. The reactions were
stopped by the addition of 5 mM EDTA and formamide loading
buffer, and analyzed on 12% denaturing sequencing gels. Products
were quantified using the Typhoon imaging system.
Molecular dynamics computer simulations
Four HIV-1 RT structures were selected to provide the starting
structures for our molecular dynamics simulations. The structures
chosen contain HIV-1 RT bound to NVP (PDB: 1VRT), double
stranded DNA (PDB: 2HMI), a hybrid RNA/DNA duplex based
on the polypurine tract (PDB: 1HYS) and the apo enzyme (PDB:
1DLO). The sequences of the template strands of the double
stranded DNA and RNA/DNA hybrid complexes are 59-
GTCCCTGTTCGGGCGCCAC-39 and 59-UCAGCCACUUU
UUAAAAGAAAAG-39 respectively. The later sequence repre-
sents a sequence similar to that of the HIV PPT.
Models of the NL4.3 wildtype and incorporating T400
sequences were generated via homology modelling using a
combination of the VMD [42] and Deepview (formerly known
as Swiss-PDBViewer) packages [43]. In each case the final model
contains 556 residues in the first (p66) chain and 427 in the second
(p51) chain for a total of 983 residues. Each system was solvated
using a cubic box of TIP3P water molecules [44] providing a
buffer of at least 14 A˚ distance around the protein. The systems
were neutralized by the addition of Cl2 ions for the apo enzyme
and NVP bound complexes and Na+ ions for those containing
nucleic acids. No Mg2+ ions were present in any of the crystal
structures and none were added. The final models (including
solvent) contained approximately 180,000 atoms. The force field
parameters for the inhibitor NVP were described using the
General AMBER Force Field (GAFF) [45]. The protein and
nucleic acid elements of all systems were described by the standard
AMBER force field (ff03) [46]. Simulations for each system
produced 20 ns of production simulation (following a 6 ns
equilibration run) using the NAMD2 software [47] in isother-
mal-isobaric (NPT) conditions, with a temperature of 300K and a
pressure of 1 bar. Full details of the simulation protocol and
equilibration analysis are provided in the supporting information
(Fig S1–S3 and Table S1 in File S1). Protein structural analysis
was performed using VMD [42] and the AmberTools [48]
software and nucleic acid conformations via 3DNA [49,50].
Results
Increased frequency of T400 in HIV-1 subtype B
individuals failing therapy
The complete RT sequence of 135 HIV-1 subtype B patients in
France was sequenced to identify novel mutations in the
connection and RNaseH domain of RT involved in drug
resistance. The RT sequences derived from the 48 drug-naı¨ve
Position 400 in HIV-1 RT Affects NNRTI Resistance
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e74078
and the 87 RTI-treated patients were analyzed. From the treated
patients, 28% received a therapy containing NRTIs (median of 5
NRTIs), whereas 72% received a therapy containing both NRTIs
and NNRTIs. We identified 17 positions significantly associated
with RTI exposure (Table 1). Among them, 13 were located in the
polymerase domain and are known to be associated with RTI
resistance (M41, K65, D67, T69, K70, L74, K103, Y181, M184,
G190, L210, T215 and K219) [51]. Three other polymerase
domain mutations (K43, V118, and L228) were previously
reported to be associated with NRTI therapy [52–55]. In addition,
position 400 in the connection subdomain of RT was identified
(Table 1). Position 400 is polymorphic in naı¨ve patients, alanine is
present in 51%, threonine in 41%, and other residues are found in
8% of the sequences. However, in patients failing therapy, A400 is
present in 22%, T400 in 72% and other residues are found in 6%
of the sequences. We thus observed an increase in the presence of
T400 in patients failing therapy. The relationship between position
400 and mutations in the polymerase domain was investigated.
Eleven out of 16 mutations were found significantly associated
with position T400 (p,0.05 in Table 2). In particular, T400 was
found in 65% of the viruses harbouring mutation M184V/I, and
in 57% of the viruses containing mutation T215Y/F. An
association with several other TAMs, and three positions involved
in NNRTI resistance (103, 181 and 190) was found, as is
summarized in Table 2 (p,0.05). Further analysis was performed
to determine the association of T400 with specific virologic and
therapeutic parameters. We identified treatment experience
(p = 0.0009) and zidovudine (AZT) (p = 0.05), abacavir (ABC)
(p = 0.006) or nevirapine (NVP) (p = 0.02) exposure, presence of at
least one TAM (p = 0.0006), at least 4 NRTIs received in the past
(p,0.0001) and NNRTI exposure (p = 0.001) to be associated with
the presence of T400. Furthermore, prior exposure to ABC
(OR = 4.34, p = 0.014) and to NVP (OR = 3.66, p = 0.046) were
independently associated with T400. Treatment with either ABC
or NVP thus resulted in an approximate four-fold increase in the
presence of a threonine at position 400.
Drug susceptibility of viruses containing substitution
A400T
To analyze the role of T400 in the connection subdomain of
HIV-1 RT in drug the resistance, we substituted the alanine at
position 400 by threonine in the HIV-1 molecular clone pNL4.3-
XN by site-directed mutagenesis. Given that we observed a strong
association between T400 and polymerase mutations M184V,
mutation T215Y and several other TAMs, we also introduced the
A400T substitution into molecular clones containing the M184V
mutation or TAMs M41L and T215Y. Single-cycle drug
susceptibility assays showed that the A400T substitution reduced
susceptibility to NVP and EFV approximately 5-fold and 2-fold,
respectively (Fig 1A). The susceptibility to the second generation
NNRTI etravirine was not significantly changed. These effects on
susceptibility were measured in the wild-type background, and
independent of the presence M184V or TAMs (results not shown).
These results show that T400 alone confers low-level resistance to
these NNRTIs. However, T400 by itself did not affect the
sensitivity to NNRTIs (Fig 1A), neither did it combined with the
M184V or TAM mutations (results not shown).
Replication capacity of A400T viruses
To study the replication potential of the viruses containing
T400, we used equal amounts of virus to infect SupT1 cells
(Fig. 1B). These cells express the CD4-CXCR4 receptors, and are
fully susceptible for replication of the pNL4.3 strain. Virus
production was followed by measuring CA-p24 levels in the
culture medium at several days after infection. The replication of
the A400T virus was reduced compared to the wild-type virus,
T400 also reduced the replication capacity of the M184V and
TAM viruses. Similar results were obtained upon direct transfec-
tion of the molecular clones into the SupT1 cell line (results not
shown). These results show that a fitness cost is associated with
Table 1. Changes in the RT sequence of HIV-1 subtype B
viruses that are found with increased frequency in patients
failing therapy.
HIV-1 patients (%)
Rank
Mutated
position
Corrected p-
valuea,b Naive Treated
1 M184 ,0.0001 0 84
2 T215 ,0.0001 4 70
3 M41 ,0.0001 0 60
4 D67 ,0.0001 0 51
5 K219 ,0.0001 4 45
6 V118 ,0.0001 2 39
7 L74 0.00034 0 29
8 K43 0.00062 0 28
9 L210 0.00099 6 40
10 K103 0.00233 0 24
11 T69 0.00324 2 29
12 K70 0.00361 0 23
13 L228 0.01271 0 21
14 K65 0.03923 0 17
15 Y181 0.03923 0 17
16 G190 0.03923 0 17
17 A400 0.04219 49 78
aCorrection based on the False Discovery Rate (FDR) approach.
bp-values ,0.05 are considered significant.
doi:10.1371/journal.pone.0074078.t001
Table 2. Association between position 400 (alanine vs
threonine) and polymerase domain mutations in subtype B
viruses from patients failing therapy.
Mutated
position p-value* A400 (%) T400 (%)
M184 0.0004 30 65
T215 0.0036 28 57
L74 0.0037 5 27
V118 0.0045 10 34
K70 0.0063 3 22
D67 0.0086 18 42
K103 0.0112 3 19
K219 0.0229 18 39
M41 0.0310 25 46
Y181 0.0357 3 17
G190 0.0357 3 17
*p-values ,0.05 are considered significant.
doi:10.1371/journal.pone.0074078.t002
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replacing the alanine at position 400 with a threonine in the HIV-
1 NL4.3 virus strain.
Effect of A400T on polymerase activity
To characterize the effects of T400 on polymerase function, the
activity of the virion-derived RT enzymes was analyzed (Fig. 2).
Therefore, viral lysates were generated and normalized for the
amounts of CA-p24. We used an RNA template encompassing the
HIV-1 primer binding site (PBS) region and a labeled DNA
primer complementary to the PBS (Fig 2A). Minus-strand DNA
synthesis was initiated by the addition of virion-derived RT and
dNTPs. Extension of the 21-nt primer results in increasing
amounts of the 38-nt labelled cDNA product over time for the
wild-type RT (Fig 2B, lanes 1–3). The amounts of cDNA products
generated by the different virion-derived RTs were quantified, and
the results of three independent experiments are plotted in Fig. 2C.
Substitution A400T did not significantly affect the polymerase
activity of the wild-type or TAM enzymes. Interestingly, the
polymerase activity of M184V was reduced compared to the wild-
type RT, and introduction of a threonine at position 400 restored
this defect.
Effect of A400T on RNaseH activity
A threonine at position 400 may influence the RNaseH activity
of the RT enzyme, as was reported for other connection
subdomain mutations [34]. We therefore investigated the RNaseH
activity of the virus-derived RTs using a 59-end-labeled RNA
template/DNA primer as a substrate (Fig 3A). RNaseH cleavage
was monitored over time, showing the formation of shorter RNA
products due to primary (position 219) and secondary cleavages
(positions 212 to 29) for the wild-type RT (Fig 3B, lanes 1–4).
RNaseH cleavage was found to depend on the presence of
magnesium (lane 17), and no degradation was observed in the
absence of RT (lane 18). Formation of secondary cleavage
products was quantified for the different virion-derived RTs
(Fig 3 B/D). Mutation M184V did not affect RNaseH cleavage of
the RNA template compared with the wild-type RT (Fig 3 B/C).
However, substitution A400T reduces RNaseH activity in both the
wild-type and M184V genetic backgrounds. Furthermore, TAM
mutations did not affect RNaseH cleavage compared with the
wild-type RT, whereas T400 in this background reduces RNaseH
activity (Fig 3 D/E). These results indicate that threonine at
position 400 reduces RNaseH activity both on its own and when
combined with M184V or TAMs.
Conformational changes in RT mediated by A400T
Residue 400 is located distant from both the NNRTI binding
pocket and the RNaseH active site, but was found to impact both
drug susceptibility and enzymatic function. To investigate the
structural changes in RT mediated by the alanine to threonine
change at position 400, we performed molecular dynamics
simulations. In the p51 subunit, residue 400 is located close to
two residues involved in the RNaseH primer grip, K395 and E396
(all three residues are found in the alpha helix conventionally
labeled aL [2] (Fig 4). The RNaseH primer grip has been shown to
help position the template/primer complex at the RNaseH active
site [56,57]. In p66 these residues are located in a solvent exposed
helix far from the functionally significant regions of the protein (see
Fig S1 in File S1). We have previously demonstrated that the
region around aL in p51 can be impacted by the binding of NVP
[33]. The aim of our simulations is to test whether the change at
position 400 alters the dynamics of residues in the RNaseH primer
grip and whether any such changes are correlated with alterations
in the template/primer trajectory or conformation. Simulations
were performed on the NL4.3 wild-type and A400T HIV-1 RT
enzyme bound to DNA/DNA and RNA/DNA template/primer
complexes. These simulations were also performed for the RT
enzyme bound to NVP. A 20 ns simulation trajectory was
generated for the different RT complexes. No significant
differences in the overall structure and flexibility of the polymerase
domain or conformation of the RNaseH domain were observed
between the wild-type and A400T enzymes for any of the
simulated complexes, apart from in the highly flexible p66 fingers
subdomain (see Fig S4–S7 in File S1). However, changes were
observed in the region surrounding residue 400 in p51, which was
therefore analyzed in more detail.
In all simulations with a threonine at position 400 a stable
hydrogen bond is formed between the side chain oxygen of T400
and E396 (Fig 4B/C). We propose that formation of this hydrogen
bond results in subtle changes in the backbone of the aL helix. To
Figure 1. Drug susceptibility and replication of A400T viruses. (A) Susceptibility of the A400T virus to NNRTI (light grey) and NRTI (dark grey)
was measured using single-cycle drug susceptibility assays. The average of three independent experiments is plotted, and the standard deviation is
shown (error bars). The susceptibility of the A400T virus is shown as the relative difference in IC50 compared to the wild-type pNL4.3-XN virus. (B)
Replication of viruses containing A400T alone, or in combination with M184V or TAMs. SupT1 cells were infected with an equal amount of virus
(50 ng). CA-p24 production was measured in the culture medium at several days post infection. A representative experiment is shown. Three
independent experiments were performed with similar results.
doi:10.1371/journal.pone.0074078.g001
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investigate how these affect the RNaseH primer grip we measured
the side chain dihedral angles of p51 residues K395 and E396 (Fig
S8–S10 in File S1). No significant changes were observed in the x1
dihedral of residue 395. Differences are however evident in the x1
dihedral angle of E396. The flexibility of the sidechain in the
RNA/DNA-bound A400T RT enzyme was greater than that in
the wild-type RT complex (Fig 5A and Figure S9 in File S1). In
wild-type RT only angles close to 190u are found, whereas in
A400T the distribution of angles is bimodal with peaks around
180u and 80u. Interestingly, the opposite change in flexibility was
observed for the RT enzymes bound to the DNA/DNA complex.
Only a single peak is found in the x1 angle distribution for the
A400T enzyme, and a bimodal distribution is observed for the
wild-type (Fig 5B). As we have previously shown [33], this region is
also impacted by the binding of NVP with both RT enzymes
showing bimodal distributions with peaks around 90u and 170u
(Fig 5C). In wild-type RT, the 170u angle is more frequently
observed, whereas the 90u angle is more frequent for A400T. This
suggests that a threonine at position 400 would be able to oppose
the effects of NVP binding to the DNA/DNA template/primer
RT complex.
The differences observed in E396 change the pattern of salt
bridging between this residue and p66 residues 356 and 358. In
the 2HMI crystal structure (used as the basis for the DNA/DNA
simulations) a salt bridge is formed between residues 396 and 358.
During the simulations of the DNA-bound RT two conformations
are sampled, one which maintains the salt bridge with residue 358
with an average length of 2.81 A˚, and another in which a salt
bridge forms with residue 356 with an average length 2.90 A˚.
These residues are in a loop that links directly to residues within
the RNaseH primer grip. We observe that these small changes in
residue flexibility are accompanied by larger scale changes in the
orientation of p51 K395 and E396 relative to p66 primer grip
residues 356 and 358 in the RNaseH domain. The angle between
the p51 and p66 residues was affected by template/primer- and
NVP-binding for both the wild-type and A400T RT (Table 3 and
Fig S11 in File S1). The largest change was measured with the
A400T RT upon binding of the DNA/DNA complex. The angle
was reduced to 64u for A400T, whereas an angle 110u of was
measured for the wild-type RT. The orientation of the primer grip
residues was less affected in the A400T RT by binding of the
RNA/DNA complex or NVP compared to the wild-type. This
suggests that the RNA template may not be correctly aligned for
degradation when a threonine is present at position 400 in RT and
this effect may be enhanced by NVP binding.
We then investigated if T400 in the RNaseH primer grip changes
the template/primer trajectory. The distance between the scissile
phosphate (219) and the centre of mass of the RNaseH active site
(p66 residues 443, 478, 498 and 549) was analyzed over the course
of the simulations (Fig 5D). We detected a constant distance of
around 6.5 A˚ for the wild-type RT. This distance is more variable in
the A400T RT, for which values between 6 and 9.5 A˚ were
observed. These changes in the trajectory of the template/primer
suggest that the A400T RT is less capable of maintaining the
catalytic conformation. The incorrect orientation of the scissile
phosphate relative to the catalytic residues may result in reduced
RNaseH cleavage. Alongside the alteration of the template
trajectory and conformation we observe changes in the flexibility
of the template. The RNA template was found to be more flexible
than the DNA template in the primer/template-bound RT
Figure 2. DNA polymerase activity of virus-derived RT enzymes containing substitution A400T. (A) DNA polymerase activity was
measured using a 51-nt RNA template, representing the HIV-1 primer binding site (PBS) with flanking sequences. A 21-nt DNA primer complementary
to the PBS was 59-end-labeled (asterisk), and heat-annealed onto the RNA template. Extension of the primer by RT will result in a 38-nt labeled cDNA
product. (B) The RNA template/DNA primer complex was incubated with the different virion-derived RTs in the presence of dNTPs. Formation of the
cDNA product (cDNA) was monitored after 3, 7 and 15 min incubation. A control reaction was performed in the absence of RT (lane 19) showing only
the labeled primer (P). (C) The amount of cDNA production was quantified in three independent experiments. Plotted is the average cDNA
production with standard deviation (error bars). The polymerase activity of the wild-type virus-derived RT was set at 100%.
doi:10.1371/journal.pone.0074078.g002
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simulations (S12–S13), which is in agreement with experimental
evidence [58]. It has been suggested that these differences are
responsible for substrate recognition by RNaseH. Particularly
flexible is the region between base pairs 210 and 212, which
corresponds with the location of p51 residues 395 and 396 in the
RNaseH primer grip.
It has been suggested that recognition by HIV-1 RT of
template/primer complexes, and their alignment by the primer
grip [56], is influenced by the width of the substrate minor groove
[59,60]. The RNaseH primer grip residues directly interact with
the minor groove and alterations in its width and flexibility are
observed between alanine and threonine at position 400 in our
simulations (Fig S12–S15 in File S1). The largest changes were
observed between bases 212 and 214 of the DNA/DNA complex
bound to the A400T RT enzyme, although these may be
exaggerated by the short length of the simulated duplex. These
Figure 3. RNaseH activity of virus-derived RT enzymes containing substitution A400T. (A) RNaseH cleavage was measured using a 59-end
labeled (asterisk) 51-nt HIV-1 RNA template representing the PBS region. A 21-nt DNA primer complementary to the PBS was heat-annealed onto the
RNA template. Primary (219) and secondary (212/29) cleavages were monitored. (B) Representative gel showing RNaseH cleavage mediated by the
virion-derived RTs with substitution A400T in the wild-type and M184V background. The reactions were initiated by the addition of Mg2+, and
template (T) cleavage was monitored after 3, 7, 20 and 40 min of incubation. Control reactions were performed in the absence of Mg2+ (lane 18) or RT
(lane 19), showing no template degradation. (C) The formation of secondary cleavage products over time was quantified, and is plotted for this
representative gel. (D) RNaseH cleavage mediated by the virion-derived RTs with substitution A400T in the wild-type and TAM background was
analyzed, and formation of secondary cleavage products is plotted in (E). Representative experiments are shown, and three independent experiments
were performed with similar results.
doi:10.1371/journal.pone.0074078.g003
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effects are in agreement with the detected change in the primer
grip angle (Table 3). For both template/primer complexes the
changes in flexibility and minor groove width are only local to the
RNaseH (and primer grip) domain, and do not affect the
conformation at the polymerase active site. These combined
results suggest that T400 affects the conformation of the RNaseH
primer grip, and changes the position of the RNA template
relative to the scissile phosphate in the RNaseH active site. This
conformational change is likely to reduce the catalytic rate and
explains the reduced RNaseH cleavage that was measured for
A400T RT in biochemical assays (Fig 3).
We also investigated the structural effects of position 400 in
other HIV-1 subtype B isolates. The HXB2 isolate contains a
threonine at position 400, and crystal structures indicate that this
forms the same hydrogen bond with E396. However, several
residues near position 400 differ between the NL4.3 and HXB2
viruses. For instance, the p66 residue 376 is located in close
proximity to the aL helix that contains residue 400 in p51 (see Fig
S17 in File S1). The NL4.3 virus contains hydrophobic alanine
residues at positions 400 and 376, whereas HXB2 contains polar
threonine residues. The favourable interactions between positions
376 and 400 allow close packing at the dimer interface. This is
disrupted by substituting alanine for threonine in NL4.3, resulting
in distortion of the local geometry. We noticed that the residues at
positions 376 and 400 co-vary in different HIV-1 subtype B
isolates. In the Los Alamos HIV database, 37% of the sequences
contain A400, whereas 52% contain T400. Analysis of the
sequences with A400 shows that 81% has an alanine, and only
17% has polar threonine or serine residues at position 376. In
contrast, when T400 is present, the frequency of T/S376 is
increased to 43%, whereas A376 is reduced to 54%. This co-
variation is highly significant (p,0.0001), however other residues
are likely to play a role as the T400/A376 combination is found in
approximately half of the subtype B sequences. Local interactions
in the RT protein thus may determine the selection of alanine or
threonine at position 400 in HIV-1 subtype B viruses.
Discussion
Mutations in the connection and RNaseH domains of HIV-1
RT were previously found to confer resistance to NRTI and
NNRTI [26,27]. In this study, we identified a novel role for
polymorphism T400 in the connection domain of RT. We
analyzed the complete RT sequences of 135 naı¨ve and treated
patients infected with subtype B HIV-1 in France. Position A/
T400 is polymorphic in naive individuals, but T400 occurs more
frequently in patients failing therapy. No other statistically
significant mutations in the connection or RNaseH domain were
found to be associated with treatment failure. Several positions
involved in NRTI and NNRTI resistance were found to be
associated with T400, in particular M184V/I and T215Y/F. To
study the role of position 400 in drug resistance, the alanine at
position 400 in the reference strain NL4.3 was substituted by a
threonine using site-directed mutagenesis. Substitution A400T was
also introduced in combination with M184V and TAMs T215Y
and M41L. Drug susceptibility assays demonstrated that T400
mediates low-level resistance to NVP (5-fold IC50 increase) and
EFV (2-fold) in the wild-type NL4.3 background. However, T400
alone, or in combination with M184V or TAMs, did not affect the
sensitivity for NRTIs. An increase in proportion of T400 was
found to be associated with exposure to NVP in treated HIV-1
patients, which is consistent with the measured decrease in NVP
susceptibility. In addition, an association was found with exposure
to AZT and ABC, but no change in susceptibility to these NRTIs
was measured.
Analysis of the RT sequences showed a 41% prevalence of
T400 in untreated patients, which increased to 72% in patients
failing therapy. A previous study also reported an increase in the
frequency of T400 from 43% in naı¨ve to 69% in treated subtype B
patients in Brazil [28,29]. We analyzed the prevalence of T400 in
two major HIV sequence databases. The Los Alamos HIV
database collects published HIV sequences that were not
generated during drug resistance studies, whereas the Stanford
HIV drug resistance database accepts sequences only from
patients developing virological failure. The prevalence of T400
varies between 52% in the Los Alamos database to 41% in the
Stanford database for untreated HIV-1 subtype B patients. The
increase in the frequency of T400 in treated patients is not found
in the Stanford database. Analysis of the database at Janssen
Diagnostics in which the results of 446007 Antivirogram
phenotypic assays are collected [61], showed a 76% prevalence
of T400, combined with reduced susceptibility to the NNRTIs
NVP, EFV and ETR. Differences in the time and place of
infection, risk group or route of infection of the patient sequences
collected in France, Brazil and the databases may have resulted in
differences in the prevalence of T400. Differences in treatment
regime or time of sampling after failure may account for variation
in the percentage of T400 found after treatment. Furthermore,
viruses with classical NNRTI resistance mutations (such as
K103N, Y181C) in the polymerase domain may eventually
replace the viruses with T400 due to much higher resistance
levels conferred by these mutations.
Figure 4. Structure of the HIV-1 reverse transcriptase (RT)
enzyme. (A) Shows RT bound to a DNA/DNA template/primer complex
(shown in surface representation). The enzyme is shown in cartoon
representation and coloured by subdomain; fingers are blue, palm red,
thumb green, connection yellow and the RNaseH orange. The p66
subunit is shown in the foreground and in darker shades. A black
rectangle indicates the location of the p51 RNaseH primer grip. (B) and
(C) show detailed views of this region, including chemical representa-
tions of the residues K395 and E396 in the wild-type and A400T RT
enzymes, respectively. A green line is used to illustrate the hydrogen
bond formed between T400 and E396.
doi:10.1371/journal.pone.0074078.g004
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Previous studies that analyzed HIV-1 subtype AE and C
sequences also showed an increased prevalence of polymorphism
T400 after treatment. In subtype AE, T400 was found to be
associated with NRTI treatment [30,31]. In the presence of four
TAM mutations (D67N, K70R, T215Y and K219Q), residue
T400 was found reduce the susceptibility to AZT by increasing its
excision [31]. In subtype C, T400 mediated a two-fold increase in
AZT resistance when combined with four TAM mutations [32].
However, in our study in the HIV-1 subtype B NL4.3 background,
T400 did not further increase resistance to AZT mediated by the
two TAM mutations M41L and T215Y. These results suggest that
the background, and the number and specific (combinations of)
TAM mutations determine the levels of AZT resistance conferred
by polymorphism T400.
This is the first study to describe resistance to NNRTIs
mediated by position T400 in RT. Susceptibility to NVP was
reduced 5-fold, whereas that of EFV was reduced 2-fold in the
wild-type NL4.3 background. A number of other amino acid
substitutions in the RT connection subdomain have been
associated with low-level (,2-fold) resistance to NNRTIs [27].
In some cases, the residues involved occur at the NNRTI binding
pocket and participate in interactions with the inhibitor (e.g.
Y318F/W) [62,63]. But most drug resistance mutations occur
away from the NNRTI binding pocket. The molecular mecha-
nisms involved in resistance mediated by these mutations are less
clear and still being investigated. The most extensively studied
mutation is N348I, which provides resistance to AZT and NVP
[23,64–68]. This mutation was shown to reduce the rate of RNA
Figure 5. Distance between the scissile phosphate (219) and the centre of mass of the RNaseH active site (p66 residues 443, 478,
498 and 549) over the course of the simulations of the HIV-1 RT bound to an RNA/DNA substrate. The simulation for the wild-type A400
is shown in red, and for substitution T400 in blue. Frequency distributions of the x1 dihedral of p51 residue E396 in simulations of (B) RNA/DNA hybrid
substrate, (C) double stranded DNA substrate and (D) NVP bound HIV-1 RT (results for the unbound RT are shown in Fig S16 in File S1). The simulation
for A400 is shown in red, T400 in blue.
doi:10.1371/journal.pone.0074078.g005
Table 3. The average angle between RNaseH primer grip
residues in the p51 (residues 395 and 396) and p66 (359 and
360) subunits observed in simulations of HIV-1 RT with alanine
and threonine at position 400.
A400 T400
Unbound 130u (8) 121u (11)
DNA/DNA 102u (6) 64u (7)
RNA/DNA 110u (7) 120u (8)
NVP 94u (9) 103u (11)
Standard deviations are shown in parentheses.
doi:10.1371/journal.pone.0074078.t003
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template degradation by RT, giving RT more time to excise the
blocking nucleoside analogue from the terminated primer [23,69].
A general model to explain dual resistance to NRTI and NNRTI
based on RNaseH activity has been proposed [35]. Reduced
RNaseH cleavage of the RNA template will allow more time for
dissociation of the NRTI from the RT-template/primer complex,
leading to more efficient re-initiation of DNA synthesis.
Consistent with this model, we measured reduced RNaseH
activity due to T400 in the HIV-1 NL4.3 isolate either alone or
when combined with M184V and TAMs. These results suggest
that this substitution decreases sensitivity to NVP and EFV by
reducing RNaseH cleavage of the RNA template, allowing more
time for dissociation of the inhibitor and continuation of DNA
synthesis. Interestingly no significant resistance to the second
generation NNRTI ETR was measured. ETR represents a
different class of inhibitors, that is able to bind the enzyme RT
in multiple conformations and thereby escape the effects of drug-
resistance mutations [70]. EFV is known as a tight binding
inhibitor [71], whereas NVP dissociates more frequently from the
RT-template/primer complex [72]. This may explain the higher
resistance to NVP (5-fold) compared to EFV (2-fold).
We show that the A400T substitution did not affect the DNA
polymerization activity of the wild-type and TAM RTs. However,
a reduced polymerase activity was measured for the M184V
mutant, as was previously reported [18–20]. Residue T400 was
found to restore the polymerization defect mediated by M184V
(Fig 2). The process of reverse transcription depends on a delicate
balance between DNA synthesis and RNA degradation. Substitu-
tion A400T reduces RNA template degradation, which may
provide more time for the less processive M184V mutant RT
enzyme to reverse transcribe the RNA template. Similar results
were obtained for mutation N348I, which was also shown to
compensate for mutation M184V [73]. Substitution A400T was
found to reduce the virus replication capacity in the absence of
inhibitors, also in the M184V background. Thus, although T400
was able to restore the polymerization defect of M184V, the
reduced RNaseH activity may affect other steps in the reverse
transcription process, such as strand-transfer and primer-removal,
resulting in reduced replication. These findings imply a fitness cost
is associated with the alanine to threonine change at position 400
in the HIV-1 NL4.3 virus strain. Our structural analysis suggests
that this is the result of distortion of the region surrounding
position 400, as the polar threonine clashes with the hydrophobic
alanine at position 376. However, in other HIV-1 isolates, as for
example HXB2, T400 is combined with T376 which compensates
for these structural changes. Substitution T376, and possibly other
local interactions, thus may restore the replication defect mediated
by T400, explaining the presence of the T400 in a proportion of
the naı¨ve HIV-1 subtype B patients. In addition, we showed that
replication of the wild-type NL4.3 virus was more severely affected
by the A400T substitution than replication of the M184V and
TAM viruses. This indicates that polymerase mutations can partly
compensate for the replication defect associated with T400.
It is curious that our data demonstrate a strong association of
T400 with M184V/I despite it having no significant effects on
drug susceptibility in the context of M184V, and no positive effects
on viral fitness. One possible explanation for this may lie in the
previously observed antagonism between M184V and TAMs.
Mutation M184V suppresses the resistance conferred by TAMs,
although this effect decreases with an increase in the number of
TAMs [74]. It is possible that T400 might be involved in
facilitating dual resistance to AZT and 3TC resistance in viruses
that harbour both TAMs and M184V, as was suggested for
mutations G333D/E and N348I in the connection subdomain
[75,76]. Further studies in which substitution A400T is introduced
in a background with more TAM mutations in combination with
M184V will be needed to address this possibility.
Using molecular dynamics simulations we provide a novel
atomistic mechanism for the changes in the RNaseH activity
induced by the alanine to threonine change at position 400 in the
HIV-1 RT. The position is located far from both the polymerase
and RNaseH active sites of the enzyme. Simulations showed no
significant differences in the structure and flexibility of the
polymerase domain, but changes were observed in the RNaseH
domain. A hydrogen bond is formed in the p51 subunit between
residue T400 and E396 which is part of the RNaseH primer grip
(Fig 4). This hydrogen bond was also found in simulations of
template/primer- and NVP-bound RT with a threonine at
position 400. Simulations showed that the distance between the
scissile phosphate (219) and the RNaseH catalytic centre is more
flexible for T400. This may result in the incorrect orientation of
the scissile phosphate relative to the RNaseH catalytic residues.
We also show that T400 changes the salt bridging in the primer
grip region, thereby changing the orientation of several residues in
the primer grip. The RNaseH primer grip residues directly
interact with the minor groove of the RNA/DNA substrate, and
changes were detected in the width of the minor groove. Our
simulations suggest that substitution A400T changes the confor-
mation of the RNaseH primer grip region. We have proposed a
detailed mechanism in which these changes are initiated by a
hydrogen bond between T400 and E396, however further
structural studies are required to more completely describe the
molecular basis of the effects we have observed. The structural
changes in the RNaseH primer grip alter the trajectory of the viral
RNA genome, thereby reducing the accessibility of the correct
catalytic conformation. These changes likely decrease the RNaseH
catalytic rate of the A400T RT, leading to reduced RNaseH
cleavage. These results support the previous hypothesis that the
T400 substitution in subtype AE may disrupt the interaction with
E396, thereby altering the primer grip region and reducing RNase
H activity [31]. The slower degradation of the viral RNA genome
may provide more time for dissociation of the bound NNRTI from
the stalled RT-template/primer complex. Consequently the RT
enzyme can resume reverse transcription, explaining the observed
resistance. NVP binding was observed to impact the conformation
of the same region, further supporting the hypothesis that
interactions between the RNaseH primer grip and NNRT binding
pocket are responsible for the resistance mediated by the A400T
substitution.
The extent to which connection and RNaseH domain
mutations influence a patient’s clinical outcome is yet to be
determined. However, it is evident that several mutations in the
connection and RNaseH domains have increased prevalence
amongst treatment-experienced patients, and contribute to drug
resistance. In this study, we demonstrated that a threonine at the
polymorphic position 400 confers low-level but significant
resistance to the NNRTIs NVP and EFV in the HIV-1 subtype
B NL4.3 background. We found an association between T400 and
resistance mutations M184V/I, TAMs and several positions
involved in NNRTI resistance. Previous studies reported resistance
to AZT mediated by T400 in subtypes AE and C combination
with four TAM mutations [31,32]. These results suggest that drug
susceptibility of viruses containing T400 may depend on the
number and specific (combinations of) mutations in the polymer-
ase domain. Future studies will focus on the effects of T400 in
combination with NNRTI resistance mutations, e.g. K103N or
Y181C. Since T400 is highly associated with both M184V and
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TAM mutations, it will also be interesting to determine if T400
can counteract the antagonism between M184V and TAMs.
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